PLYMOUTH MEETING, Pa., Aug. 19 /PRNewswire/ -- ONCURA, the leading provider of minimally invasive prostate cancer treatment products, and Amerinet, a leading health care group purchasing organization (GPO), announced today that ONCURA has been awarded a three-year brachytherapy contract to continue to provide Amerinet members with a complete line of brachytherapy seeds products.
The dual source agreement will begin on September 1, 2005, and will run for a three-year term. The agreement with ONCURA offers Amerinet’s membership competitive market pricing and continued access to a complete and clinically proven Iodine-125 and Palladium-103 brachytherapy product portfolio. ONCURA has been the exclusive supplier of brachytherapy seeds on Amerinet’s contract since April 2000.
ONCURA was created through the merger of Amersham plc’s (now GE Healthcare) brachytherapy business and Galil Medical Ltd’s urology business. Galil is a subsidiary of Elron (ELRN). Headquartered in the United States, ONCURA operates as an independent business, with a major presence in the treatment of prostate cancer. ONCURA’s International business is operated from its UK subsidiary. Please visit http://www.oncura.com for more information.
Amerinet is one of the most innovative and effective health care group purchasing organizations in the United States, partnering with members to improve their operating margins. Amerinet leads the industry in flexibility with a commitment to providing supplier choice for its members. Amerinet’s national network of companies - Amerinet Central, Intermountain Health Care and Vector - has set the standard for customer service for nearly two decades. More than 1,900 hospitals and 22,000 non-acute care facilities find cost savings and value-added services through Amerinet’s comprehensive contract portfolio.
ONCURA
CONTACT: Andrew Bright, ONCURA, +1-484-530-3922, andrew.bright@oncura.com
Web site: http://www.oncura.com/
